Galloway Thomas J, Pugh Stephanie L, Ridge John A, Nguyen-Tan Phuc Felix, Rosenthal David I, Gillison Maura, Garden Adam S, Dunlap Neal, Caudell Jimmy J, Jones Chirstopher U, Bauman Jessica R, Bahig Houda, Shenouda George, Currey Adam, Koyfman Sholom A, Stokes William A, Read Nancy, Lyness Jessica A, Yom Sue S, Le Quynh-Thu
Fox Chase Cancer Center, Philadelphia, Pennsylvania.
NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.
Int J Radiat Oncol Biol Phys. 2025 Jun 3. doi: 10.1016/j.ijrobp.2025.05.064.
The rate of long-term feeding tube usage for patients treated with definitive (chemo)radiation is unknown. This analysis aims to determine predictive factors of feeding tube use years after treatment completion on NRG Oncology head and neck cancer trials that accrued from 2002 to 2014.
This is an unplanned, post hoc secondary analysis in the long term of both oropharynx cancer (OPC) and all treated patient feeding tube rates 6 months to 9 years after chemoradiation completion for patients treated on the multicenter prospective trialsNRG/RTOG 0129, 0522, and 1016.
Median (min-max) follow-up was 6.7 years (interquartile range, 3.4-8.2) for OPC patients. Five hundred ninety-eight of 1839 (33%) OPC patients had a feeding tube 6 months after treatment. This decreased to 4% at 1 year and 3% at 9 years. Predictors of a feeding tube posttreatment were treatment with 3D conformal (3DCRT) accelerated chemoradiation with concomitant boost (AFX3DCRT), older age, feeding tube at registration, T4 tumor stage, and >10 pack-years of smoking. AFX3DCRT was independently significantly more associated with feeding tube use when compared to all other regimens. Among all treated patients (n = 2387), the median follow-up was 6.3 years (interquartile range, 2.7-8.2). Intensity modulated radiation therapy (IMRT) regimens had significantly less feeding tubes than 3DCRT (AFXIMRT + Cetux + C: hazard ratios [HR], 0.75 [0.63-0.89]; AFXIMRT + Cetux: HR, 0.81 [0.67-0.98]) for all patients. Primary site did not significantly influence feeding tube utilization (nontonsil/tongue base HR, 0.97 [0.85-1.11]).
3DCRT accelerated fractionation chemoradiation is associated with increased posttreatment feeding tube use for both OPC patients and all patients treated when compared to IMRT-based regimens. Other predictors of posttreatment feeding tube use are largely known prior to treatment initiation. Patients treated for nontonsil/tongue base primary tumors did not have higher rates of feeding tube utilization.
接受确定性(化疗)放疗的患者长期使用饲管的比例尚不清楚。本分析旨在确定在2002年至2014年进行的NRG肿瘤学头颈癌试验中,治疗结束数年之后饲管使用的预测因素。
这是一项针对口咽癌(OPC)患者以及多中心前瞻性试验NRG/RTOG 0129、0522和1016中接受治疗的所有患者在放化疗结束后6个月至9年的饲管使用率进行的非计划、事后二次长期分析。
OPC患者的中位(最小-最大)随访时间为6.7年(四分位间距,3.4 - 8.2年)。1839例OPC患者中有598例(33%)在治疗后6个月使用了饲管。1年后这一比例降至4%,9年后降至3%。治疗后使用饲管的预测因素包括采用三维适形(3DCRT)加速放化疗并同步推量(AFX3DCRT)、年龄较大、登记时使用饲管、T4肿瘤分期以及吸烟史超过10包年。与所有其他治疗方案相比,AFX3DCRT与饲管使用的相关性独立且显著更高。在所有接受治疗的患者(n = 2387)中,中位随访时间为6.3年(四分位间距,2.7 - 8.2年)。对于所有患者,调强放射治疗(IMRT)方案的饲管使用显著少于3DCRT(AFXIMRT + 西妥昔单抗 + 顺铂:风险比[HR],0.75[0.63 - 0.89];AFXIMRT + 西妥昔单抗:HR,0.81[0.67 - 0.98])。原发部位对饲管使用没有显著影响(非扁桃体/舌根HR,0.97[0.85 - 1.11])。
与基于IMRT的方案相比,3DCRT加速分割放化疗与OPC患者以及所有接受治疗的患者治疗后饲管使用增加相关。治疗后使用饲管的其他预测因素在治疗开始前大多已知。非扁桃体/舌根原发性肿瘤患者的饲管使用率没有更高。